Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The role of memantine as a treatment for Alzheimer’s disease (AD) has been controversial. In clinical trials, a high dropout rate and numerous adverse events associated with memantine have been observed. However, given the relative scarcity of effective treatments for AD it would seem prudent to re-examine existing evidence to determine whether or not memantine should be used. Eight databases were utilized for randomized controlled trials that were published prior to December 31, 2013 and were according with the inclusion criteria. Trial methods, clinical characteristics, outcomes, and adverse events were extracted and analyzed with Review Manager 5.2. We obtained 2293 studies and determined that 13 of those studies met the inclusion criteria. Memantine therapy showed significant benefits to cognition, mental state, activities of daily life, the clinician’s global impression in term with MMSE, SIB, NPI, ADCS-ADL19, CIBIC-Plus, respectively. Memantine therapy did not significantly increase the incidence of total adverse events, serious adverse events, death but it did increase the risk for somnolence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Fratiglioni L, Ronchi DD, Aguero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drug Aging 15:365–375

    Article  CAS  Google Scholar 

  2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117

    Article  PubMed Central  PubMed  Google Scholar 

  3. Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology 38:735–767

    Article  CAS  PubMed  Google Scholar 

  4. Burke D (2012) ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. Ann Intern Med 156:JC6–10

  5. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM (2007) Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement 3:7–17

    Article  CAS  PubMed  Google Scholar 

  6. Yang Z, Zhou X, Zhang Q (2013) Effectiveness and safety of memantine treatment for Alzheimer’s disease. J Alzheimers Dis 36:445–458

    CAS  PubMed  Google Scholar 

  7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Healthand Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944

    Article  CAS  PubMed  Google Scholar 

  8. American Psychiatric Association (2000) DSM-IV-TR: diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC

    Google Scholar 

  9. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341

    Article  CAS  PubMed  Google Scholar 

  10. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324

    Article  CAS  PubMed  Google Scholar 

  11. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E (2007) A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21:136–143

    Article  PubMed  Google Scholar 

  12. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G (2012) Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One 7:e35185

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Clin Psychopharmacol 33:636–642

    Article  PubMed  Google Scholar 

  14. Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, Jia XD, Pejovic V, Miller ML, Perhach JL, Graham SM (2013) The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs 27:469–478

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Herrmann N, Gauthier S, Boneva N, Lemming OM (2013) A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer’s disease. Int Psychogeriatr 25:919–927

    Article  PubMed  Google Scholar 

  16. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5:83–89

    Article  CAS  PubMed  Google Scholar 

  17. Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H, Berghold A, Windisch M, Kolassa H, Fazekas F (2008) Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. J Neurol Neurosurg Psychiatry 79:1312–1317

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14:704–715

    Article  PubMed  Google Scholar 

  19. Saxton J, Hofbauer RK, Woodward M, Gilchrist NL, Potocnik F, Hsu HA, Miller ML, Pejovic V, Graham SM, Perhach JL (2012) Memantine and functional communication in Alzheimer’s disease: results of a 12-week, international, randomized clinical trial. J Alzheimers Dis 28:109–118

    CAS  PubMed  Google Scholar 

  20. Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P (2012) Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial. J Alzheimers Dis 29:459–469

    CAS  PubMed  Google Scholar 

  21. Bakchine S, Loft H (2008) Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 13:97–107

    CAS  PubMed  Google Scholar 

  22. Winblad B, Jones RW, Wirth Y (2007) St¨offler A, M¨obius HJ: Memantine in moderate to severe Alzheimer’s disease: A meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24:20–27

    Article  CAS  PubMed  Google Scholar 

  23. Lockhart IA, Orme ME, Mitchell SA (2011) The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer’s disease: systematic review and meta-analysis. Dement Geriatr Cogn Disord Extra 1:212–227

  24. Newell DJ (1992) Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 21:837–841

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Zhizaoju Road 639, Shanghai, 200011, China

    Jue Jiang & Hong Jiang

Authors
  1. Jue Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Jiang.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, J., Jiang, H. Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials. Neurol Sci 36, 1633–1641 (2015). https://doi.org/10.1007/s10072-015-2221-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-015-2221-2

Keywords

Search

Navigation